T. Lesimple - Academia.edu (original) (raw)
Papers by T. Lesimple
Annales de Dermatologie et de Vénéréologie, 2015
Annales de Dermatologie et de Vénéréologie, 2015
Annales de Dermatologie et de Vénéréologie, 2015
Annales de Dermatologie et de Vénéréologie, 2014
Annales de Dermatologie et de Vénéréologie, 2014
Annales de Dermatologie et de Vénéréologie, 2013
Research in Immunology, 1998
Centre rkgional de lutte contre le cancer Eugthe Marquis, BP 6279, 3.5062 Rennes-cedex (France) S... more Centre rkgional de lutte contre le cancer Eugthe Marquis, BP 6279, 3.5062 Rennes-cedex (France) SUMMARY Most technical problems concerning the production of human macrophages have been resolved by cultures in hydrophobic plastic, gas-permeable bags. This process enables collection of non-adherent macrophages and is well adapted to the safety requirements of cell therapy. Under optimized cutture conditions, about one billion macrophages are currently obtained from a single leukapheresis product. In most clinical trials, macrophages have been activated by interferon-gamma (IFNy). The injections have little or no toxic effect. The anti-tumour activity of the intravenous (i.v.) administrations is more pronounced in certain protocols than in others. The mechanism remains poorly understood. In vitro, the cytolytic effect of macrophages requires cell-to-cell contact but macrophages injected i.v. show no particular tropism for tumour tissue. This could result from modifications in adhesion molecules occurring during monocyte-macrophage differentiation which might modify recruitment in inflammatory foci. Macrophages can, however, infiltrate tumour cell clusters, which could explain their improved efficacy when injected intratumorally (i.t.). Moreover, several arguments would favour the use of macrophages as human tumour antigen-presenting cells (APCs). In vitro, macrophages are as efficient as monocytederived dendriiic cells (MDDCs) in stimulating cytotoxic T lymphocyte (CTL) clones or circulating CTL precursors.
Melanoma research, 2003
The main objective of this prospective multicentre randomized phase III study was to compare a co... more The main objective of this prospective multicentre randomized phase III study was to compare a combined regimen of fotemustine plus whole brain irradiation with fotemustine alone in terms of cerebral response and time to cerebral progression in patients with melanoma cerebral metastases. Seventy-six patients were randomized to receive either fotemustine (arm A, n = 39) or fotemustine plus whole brain irradiation (arm B, n = 37). Fotemustine was administered intravenously at 100 mg/m(2) on days 1, 8 and 15, followed by a 5 week rest period, then every 3 weeks in non-progressive patients. In arm B, concomitant whole brain irradiation was performed at a total dose of 37.5 Gy (2.5 Gy/day on days 1-5 for three consecutive weeks). Although patients who received fotemustine alone had worse prognostic factors, there was no significant difference in cerebral response (arm A, 7.4%, arm B, 10.0%) or control rates (objective responses plus stable disease) after 7 weeks (arm A, 30%; arm B, 47%) ...
European Journal of Cancer, 2014
Annales de Dermatologie et de Vénéréologie, 2014
Journal of the European Academy of Dermatology and Venereology, 1998
We report two cases of patients suffering from Crohn's disease. A 58-year-old woman had presented... more We report two cases of patients suffering from Crohn's disease. A 58-year-old woman had presented two years earlier an erythematous swollen right iabium majus and a red lichenified perianal area. A topical treatment with potent corticoids was successful and she has been free of symptoms for 2 years. She comes back because of a vulvar swelling of the left labium majus. The same treatment results again in a good clinical response. A 19-year-old man presents a 2 month-old homogenous and painless swelling of the upper lip. Topical corticosteroids are ineffective but the increase in the systemic methylprednisolone dose is followed by a decrease in the swelling. Both lesions (oral and vulvar) have a granulomatous histology.
Journal of Neurosurgery, 2009
M edulloblastoMa is a malignant neuroepithelial tumor that develops in the cerebellum from plurip... more M edulloblastoMa is a malignant neuroepithelial tumor that develops in the cerebellum from pluripotent cells. It is usually considered to be a tumor of childhood. However, it can occur in patients of any age, including the elderly, 9 and ~ 25% 41 to 40% 43 of cases are diagnosed in adults. Because of the relative infrequency of medulloblastoma in older patients, the treatment outcome and prognostic factors of this subgroup are less well defined. The aim of this paper is to present experiences gained from 27 patients who were ≥ 16 years old and who were treated at our institution.
European Journal of Cancer, 2012
European Journal of Cancer, 2012
Annales de Dermatologie et de Vénéréologie, 2012
Annales de Chirurgie Plastique Esthétique, 2008
Malignant melanoma of soft parts (MMSP) (or "clear cell sarcoma") is a very rar... more Malignant melanoma of soft parts (MMSP) (or "clear cell sarcoma") is a very rare tumour that shows up without primitive skin involvement (except in subcutaneous prolongations of deep tumours), mostly predominant in the extremities of young adults. Eight files of MMSP were studied retrospectively. The mean patient is a male of 35 years old affected in an extremity (four upper, three lower and one gluteal), according to classical descriptions. The importance of radical surgery in these cases has been extensively established. Confronted with these cases, the plastic surgeon must be aware of the specifics of this rare entity to ensure its proper inclusion in his clinical suspicion. Just in case.
Oncology
To investigate the efficacy and safety of the FOLFOX-4 regimen for patients with metastatic renal... more To investigate the efficacy and safety of the FOLFOX-4 regimen for patients with metastatic renal cell carcinoma (MRCC). Fifty-nine patients (median age 59 years) pre-treated or not by cytokines (29 vs. 30) received the FOLFOX-4 regimen every 2 weeks. Three minor responses, and no complete or partial responses were obtained. The median progression-free survival was 3 months (95% CI: 2.6-3.4), the median survival 10.6 months (95% CI: 8.7-12.4), with no difference between pre-treated patients and others. Treatment was well tolerated. The FOLFOX-4 regimen is ineffective in patients with MRCC. We believe that oxaliplatin should no longer be explored in renal carcinoma.
Annales de Dermatologie et de Vénéréologie, 2015
Annales de Dermatologie et de Vénéréologie, 2015
Annales de Dermatologie et de Vénéréologie, 2015
Annales de Dermatologie et de Vénéréologie, 2014
Annales de Dermatologie et de Vénéréologie, 2014
Annales de Dermatologie et de Vénéréologie, 2013
Research in Immunology, 1998
Centre rkgional de lutte contre le cancer Eugthe Marquis, BP 6279, 3.5062 Rennes-cedex (France) S... more Centre rkgional de lutte contre le cancer Eugthe Marquis, BP 6279, 3.5062 Rennes-cedex (France) SUMMARY Most technical problems concerning the production of human macrophages have been resolved by cultures in hydrophobic plastic, gas-permeable bags. This process enables collection of non-adherent macrophages and is well adapted to the safety requirements of cell therapy. Under optimized cutture conditions, about one billion macrophages are currently obtained from a single leukapheresis product. In most clinical trials, macrophages have been activated by interferon-gamma (IFNy). The injections have little or no toxic effect. The anti-tumour activity of the intravenous (i.v.) administrations is more pronounced in certain protocols than in others. The mechanism remains poorly understood. In vitro, the cytolytic effect of macrophages requires cell-to-cell contact but macrophages injected i.v. show no particular tropism for tumour tissue. This could result from modifications in adhesion molecules occurring during monocyte-macrophage differentiation which might modify recruitment in inflammatory foci. Macrophages can, however, infiltrate tumour cell clusters, which could explain their improved efficacy when injected intratumorally (i.t.). Moreover, several arguments would favour the use of macrophages as human tumour antigen-presenting cells (APCs). In vitro, macrophages are as efficient as monocytederived dendriiic cells (MDDCs) in stimulating cytotoxic T lymphocyte (CTL) clones or circulating CTL precursors.
Melanoma research, 2003
The main objective of this prospective multicentre randomized phase III study was to compare a co... more The main objective of this prospective multicentre randomized phase III study was to compare a combined regimen of fotemustine plus whole brain irradiation with fotemustine alone in terms of cerebral response and time to cerebral progression in patients with melanoma cerebral metastases. Seventy-six patients were randomized to receive either fotemustine (arm A, n = 39) or fotemustine plus whole brain irradiation (arm B, n = 37). Fotemustine was administered intravenously at 100 mg/m(2) on days 1, 8 and 15, followed by a 5 week rest period, then every 3 weeks in non-progressive patients. In arm B, concomitant whole brain irradiation was performed at a total dose of 37.5 Gy (2.5 Gy/day on days 1-5 for three consecutive weeks). Although patients who received fotemustine alone had worse prognostic factors, there was no significant difference in cerebral response (arm A, 7.4%, arm B, 10.0%) or control rates (objective responses plus stable disease) after 7 weeks (arm A, 30%; arm B, 47%) ...
European Journal of Cancer, 2014
Annales de Dermatologie et de Vénéréologie, 2014
Journal of the European Academy of Dermatology and Venereology, 1998
We report two cases of patients suffering from Crohn's disease. A 58-year-old woman had presented... more We report two cases of patients suffering from Crohn's disease. A 58-year-old woman had presented two years earlier an erythematous swollen right iabium majus and a red lichenified perianal area. A topical treatment with potent corticoids was successful and she has been free of symptoms for 2 years. She comes back because of a vulvar swelling of the left labium majus. The same treatment results again in a good clinical response. A 19-year-old man presents a 2 month-old homogenous and painless swelling of the upper lip. Topical corticosteroids are ineffective but the increase in the systemic methylprednisolone dose is followed by a decrease in the swelling. Both lesions (oral and vulvar) have a granulomatous histology.
Journal of Neurosurgery, 2009
M edulloblastoMa is a malignant neuroepithelial tumor that develops in the cerebellum from plurip... more M edulloblastoMa is a malignant neuroepithelial tumor that develops in the cerebellum from pluripotent cells. It is usually considered to be a tumor of childhood. However, it can occur in patients of any age, including the elderly, 9 and ~ 25% 41 to 40% 43 of cases are diagnosed in adults. Because of the relative infrequency of medulloblastoma in older patients, the treatment outcome and prognostic factors of this subgroup are less well defined. The aim of this paper is to present experiences gained from 27 patients who were ≥ 16 years old and who were treated at our institution.
European Journal of Cancer, 2012
European Journal of Cancer, 2012
Annales de Dermatologie et de Vénéréologie, 2012
Annales de Chirurgie Plastique Esthétique, 2008
Malignant melanoma of soft parts (MMSP) (or "clear cell sarcoma") is a very rar... more Malignant melanoma of soft parts (MMSP) (or "clear cell sarcoma") is a very rare tumour that shows up without primitive skin involvement (except in subcutaneous prolongations of deep tumours), mostly predominant in the extremities of young adults. Eight files of MMSP were studied retrospectively. The mean patient is a male of 35 years old affected in an extremity (four upper, three lower and one gluteal), according to classical descriptions. The importance of radical surgery in these cases has been extensively established. Confronted with these cases, the plastic surgeon must be aware of the specifics of this rare entity to ensure its proper inclusion in his clinical suspicion. Just in case.
Oncology
To investigate the efficacy and safety of the FOLFOX-4 regimen for patients with metastatic renal... more To investigate the efficacy and safety of the FOLFOX-4 regimen for patients with metastatic renal cell carcinoma (MRCC). Fifty-nine patients (median age 59 years) pre-treated or not by cytokines (29 vs. 30) received the FOLFOX-4 regimen every 2 weeks. Three minor responses, and no complete or partial responses were obtained. The median progression-free survival was 3 months (95% CI: 2.6-3.4), the median survival 10.6 months (95% CI: 8.7-12.4), with no difference between pre-treated patients and others. Treatment was well tolerated. The FOLFOX-4 regimen is ineffective in patients with MRCC. We believe that oxaliplatin should no longer be explored in renal carcinoma.